You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
騰盛博藥(02137.HK)逆同業曾飆30% 長效新冠藥於內地商業化上市
騰盛博藥-B(02137.HK)長效新冠中和抗體安巴韋單抗和羅米司韋單抗聯合療法於中國商業化上市,首批抗體藥物今日實現商業放行。該股兩連升,今早逆同業突破百天線(10.25元),曾飆升30%至11.5元遇壓,現報10.36元,續漲17%,成交急增至1,679萬股。 然而,開拓藥物(09939.HK)、藍籌藥明生物(02269.HK)、康希諾(06185.HK)、信達生物(01801.HK)、君實生物(01877.HK)、復星醫藥(02196.HK)、威高股份(01066.HK)、藥明康德(02359.HK)及歌禮製藥(01672.HK)吐近1.7%-4%,後兩者最傷報113.8元及3.98元,回吐3.5%及3.9%。 恆指今早在新經濟股主導進一步跌至21,200喘定,現報21,410,僅續吐176點或0.8%。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account